Navigation Links
CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
Date:7/15/2011

DURHAM, N.C., July 15, 2011 /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced today the appointment of Thomas P. Mathers, 44, as Chief Executive Officer.

Mr. Mathers has more than 19 years of executive management, sales and marketing experience in the life sciences and medical device industry. He also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as chairman of Declion Pharmaceuticals, a company which he co-founded. Prior to CoLucid, he served as president and CEO of Peptimmune, Inc. from 2003 to 2011. Founding CEO, James F. White, Ph.D. will continue his involvement with CoLucid as scientific director.

"Tom has extensive leadership skills and brings valuable strategic, operational and transactional experience to our team at a key inflection point in the company's  growth and development," said Art Pappas, Chairman of the Board of Directors, and managing partner at Pappas Ventures. "Tom will lead the CoLucid team in formulating our phase 3 development and commercialization plans for lasmiditan," he added.

During his career, Mr. Mathers has also held positions as president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and management positions at Snowden-Pencer and Pfizer, Inc. He holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.

"I am excited to join the CoLucid team and complete the development of lasmiditan, our breakthrough first in class treatment for acute migraine. This is an area of significant unmet need since many of the currently approved therapies have unwanted side effects and are contraindicated in some patients," said Mr. Mathers.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in August 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan (COL-144), a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: info@colucid.com


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
2. GenturaDx Appoints Senior Vice President of Research & Development
3. H. D. Smith Appoints Mark de Bruin Corporate Vice President Managed Care
4. OncoSec Medical Appoints Engineering Leader
5. Tris Pharma Appoints Vice President of Human Resources
6. Cepheid Appoints Vice President of Infectious Disease Research & Development
7. InstantLabs Appoints Dr. Neil Sharma as Director of Product Development
8. Hotspur Technologies Appoints Fred Khosravi Chairman of the Board
9. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
10. TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
11. Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 Acquisition Expands ... Product Development Capabilities in North America ... . Indegene ( http://www.indegene.com ), ... acquisition of Skura Corporation,s life science business. Skura,s ... sales enablement technology for life science organizations and ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, ... by partnering with college students at University of Colorado in Boulder to create ... advertising campaigns class in the School of Journalism, who selected Beanfields as the ...
(Date:5/2/2016)... ... ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident Dr. Kari ... the Annual Meeting in Los Angeles. The first annual art forum was a platform ... attendees. , “Through art I hope to educate people about radiology and its ...
(Date:5/2/2016)... ... 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills , now ... past, many necessary dental treatments could require multiple appointments to complete. This could mean ... chair time. Not only could this be inconvenient, but it could also be overwhelmingly ...
(Date:5/2/2016)... ... 02, 2016 , ... This week Omega Institute, a premier nonprofit educational retreat ... through October. Omega is offering a record 370 in-person workshops and new online ... such widespread interest in or need for the knowledge and skills we’ve been cultivating ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known ... the kidneys, liver and pancreas. If not properly addressed, visceral fat can lead ... Internal Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral ...
Breaking Medicine News(10 mins):